Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA clears IND for phase I trial of CK-0801 for bone marrow failure syndromes

June 11, 2018

SHP2, a potential therapeutic target in KRAS-mutant tumors

June 11, 2018

Taiho studies TAS-0728 in solid tumors with HER2 or HER3 abnormalities

June 11, 2018

Pfizer initiates phase II study of PF-06730512 in primary focal segmental glomerulosclerosis

June 11, 2018

NeuroVia initiates phase I/II trial of NV-1205 in childhood cerebral adrenoleukodystrophy

June 11, 2018

Saniona to study Tesomet in phase IIa trial for hypothalamic obesity

June 11, 2018

First-in-human study evaluates AZD-4205 with osimertinib in advanced NSCLC

June 11, 2018

MaxCyte and NIH enter CRADA for sickle cell disease

June 11, 2018

Responses to M-7824 in phase I study lead to phase II trial in HPV-associated cancers

June 11, 2018

Tagrisso approved in E.U. for first-line EGFR-mutated NSCLC

June 11, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...